Key Highlights
- Founded in 2011 and based in Carlsbad, California, Acutus designed and manufactured tools for catheter-based ablation procedures used to treat arrhythmias.
- Market-data providers show AFIB trading around $0.0001 on the OTC market, with a Market Capitalisation collapsed to a negligible sum and roughly 30 million shares outstanding.
- Given the wind-down, the plausible paths are limited: continued Supply of left-heart access products under the Medtronic agreement, potential asset sales, or corporate actions affecting the remaining public shell.
- The risks are severe and largely realised.
Acutus Medical Inc (OTC:AFIB) is a cautionary tale of a once-Nasdaq-listed medical-device maker that has effectively wound down its commercial ambitions. Formerly a developer of catheter-based tools for treating cardiac arrhythmias, the company has retreated to a narrow manufacturing-and-distribution role and now trades on the over-the-counter market at a fraction of a cent.
The snapshot's flat, sub-penny quote reflects a share the market prices as nearly worthless, a status that is itself the story.
Company and Latest Development
Founded in 2011 and based in Carlsbad, California, Acutus designed and manufactured tools for catheter-based ablation procedures used to treat arrhythmias. In December 2024, the company announced a realignment of resources and operational downsizing, including plans to cut roughly 65% of its workforce. Under that restructuring, its go-forward Revenue was tied largely to the sale of left-heart access products at transfer prices under an existing distribution agreement with Medtronic, rather than to a broad commercial product portfolio.
What Is Driving Attention Around AFIB?
There is no fresh catalyst behind the ticker's appearance; the snapshot shows an unchanged, sub-penny price. Attention, such as it is, stems from the collapse itself, a former growth-stage device company whose shares moved from Nasdaq to OTC markets after a prolonged decline. The near-zero quote and minimal market capitalisation reflect a company that has stepped back from independent commercialisation rather than any new development.
Key Numbers and Company Position
Market-data providers show AFIB trading around $0.0001 on the OTC market, with a market capitalisation collapsed to a negligible sum and roughly 30 million shares outstanding. For 2024, the company reported revenue of about $20 million, buoyed by transfer-price arrangements, and a net loss of roughly $9.6 million. The revenue figure marked a sharp year-on-year jump and the loss narrowed materially from 2023, but both largely reflect a shrinking cost base rather than genuine expansion. Acutus had also amended its Credit arrangements with Deerfield-affiliated lenders as it worked to manage its liabilities. Those figures should be read against the backdrop of a Business that has been sharply downsized and reoriented toward supplying Medtronic.
What Could Come Next?
Given the wind-down, the plausible paths are limited: continued supply of left-heart access products under the Medtronic agreement, potential asset sales, or corporate actions affecting the remaining public shell. Investors would need updated filings to confirm the company's current operating status, cash position and whether it continues to report as a going concern. Any definitive delisting, deregistration or restructuring step would be material. Absent a return to independent growth, the equity's residual value rests largely on contractual cash flows tied to the Medtronic relationship.
Risks to Watch
The risks are severe and largely realised. OTC sub-penny stocks carry extreme volatility, minimal Liquidity and heightened exposure to total loss. With operations downsized and revenue dependent on a single distribution relationship, the company has little Margin for error. Information availability is itself a risk: reduced disclosure and an uncertain reporting cadence make the shares difficult to value with confidence.
Acutus Medical is no longer the growth-oriented arrhythmia-device company it once aimed to be. After a 2024 downsizing, a shift to a Medtronic-supply model and a move to OTC trading at a fraction of a cent, the AFIB story is about survival and structure rather than expansion. Investors may be watching for updated filings, any asset-sale or delisting actions, and clarity on the company's ongoing status as the developments that matter most, while treating the near-zero share price as a signal of how little the market now ascribes to the equity.






Please wait processing your request...